Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis. - Wikidata - wikimedia - TriplyDB

Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis.

Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis.

http://www.wikidata.org/entity/Q37253841

about

Application of real-time three-dimensional contrast-enhanced ultrasound using SonoVue for the evaluation of focal liver lesions: a prospective single-center study.

P2860

Q54968560-A7E3723D-2A0A-4148-9D2B-D1561D6D7229

P2860

Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis.

http://www.wikidata.org/entity/Q37253841

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 September 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Renal Cell Carcinoma Metastati ...... ve Tumor Enhancement Analysis.

@en

Renal Cell Carcinoma Metastati ...... ve Tumor Enhancement Analysis.

@nl

type

label

Renal Cell Carcinoma Metastati ...... ve Tumor Enhancement Analysis.

@en

Renal Cell Carcinoma Metastati ...... ve Tumor Enhancement Analysis.

@nl

prefLabel

Renal Cell Carcinoma Metastati ...... ve Tumor Enhancement Analysis.

@en

Renal Cell Carcinoma Metastati ...... ve Tumor Enhancement Analysis.

@nl

P1433

Q37253841-D46009A5-3687-40E6-BB2F-88A47C7174F0

P1476

Q37253841-9748C297-0845-483C-842B-A294252F2692

P2093

Q37253841-2527C2B3-D77B-4B86-A80F-536A37C040A3

Q37253841-440D9B6A-7F35-4146-9761-623914C921DE

Q37253841-5F721B81-0302-40F9-87AF-880D2F68177E

Q37253841-76871956-AD66-4B1F-B08C-44815AF5D67C

Q37253841-84FFA1B9-16F6-413B-88E0-D9C97815F710

Q37253841-99A25005-B681-4FBA-B2A6-34421322F951

Q37253841-E6BB8511-BA8D-4FAA-98D6-F8C96D20D985

Q37253841-ECAA68EB-5FFA-4504-AB15-AE7AB82AFC98

Q37253841-FB51776D-E185-4D8E-916A-DEA090D0A6FA

Q37253841-FD0A630D-C181-4933-8985-5C60C977D9DA

P2860

Q37253841-0041E6AF-B974-4DA8-9697-459F8B5ED1AF

Q37253841-01AC0275-6582-422D-B00C-A2C8A66B79D2

Q37253841-02FDD40B-452F-4BA2-9A77-D1E28A010F3C

Q37253841-06959D06-6A70-4210-BC5B-EB0E794FA94A

Q37253841-06E0063B-9259-4F8C-93F2-59E20C0982FE

Q37253841-19BFE4AA-5290-4711-8ED1-6FA9A679BCC2

Q37253841-282CAF85-7160-4F70-A190-ABEBCB3E990F

Q37253841-33B891CA-E90E-48CD-A366-5A4C65BD351C

Q37253841-42F265E5-9F86-4AC0-85AF-AED0DED1B37E

Q37253841-5B255371-023E-4DF7-ACA0-6210279CBEF0

P304

Q37253841-EE60F191-FADC-4A97-9B78-1D9E42EE912C

P31

Q37253841-4AD491C6-9203-4004-A23B-E6C58999C7E6

P356

Q37253841-61B85D65-2082-4481-9BF4-836DD26D55FF

P433

Q37253841-6802EE2D-0F02-4BC7-B59A-108199722DB0

P478

Q37253841-A574BFC2-EA9F-45DB-88BC-458234D07FCD

P50

Q37253841-A98EE902-90DE-4FAE-B7F8-D86B2ADBA210

P577

Q37253841-99B9B96A-A590-427C-8770-0257AB297AD8

P698

Q37253841-D1A0C9F1-AA77-45E2-886E-D58001EC3141

P932

Q37253841-D021CDF4-3608-4761-A32A-21CFF2E9BD4E

P356

J.TRANON.2016.07.005

P1433

Translational Oncology

P1476

Renal Cell Carcinoma Metastati ...... ve Tumor Enhancement Analysis.

@en

P2093

Bernhard Gebauer

http://www.w3.org/2001/XMLSchema#string

Florian Nima Fleckenstein

http://www.w3.org/2001/XMLSchema#string

Jae Ho Sohn

http://www.w3.org/2001/XMLSchema#string

Jean-François Geschwind

http://www.w3.org/2001/XMLSchema#string

Julius Chapiro

http://www.w3.org/2001/XMLSchema#string

Karen Marshall

http://www.w3.org/2001/XMLSchema#string

MingDe Lin

http://www.w3.org/2001/XMLSchema#string

Rafael Duran

http://www.w3.org/2001/XMLSchema#string

Rüdiger Egbert Schernthaner

http://www.w3.org/2001/XMLSchema#string

Sonia Sahu

http://www.w3.org/2001/XMLSchema#string

P2860

Targeted therapy for advanced renal cell carcinoma

Global cancer statistics, 2012

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy

Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.

Uveal Melanoma Metastatic to the Liver: The Role of Quantitative Volumetric Contrast-Enhanced MR Imaging in the Assessment of Early Tumor Response after Transarterial Chemoembolization.

Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis

Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation

P304

377-383

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.TRANON.2016.07.005

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27641641

http://www.w3.org/2001/XMLSchema#string

P932

5021812

http://www.w3.org/2001/XMLSchema#string